RamseyRE. Treatment of status epilepticus. Epilepsia1993;34(suppl):S71-81.
2.
Working Group on Status Epilepticus.Treatment of convulsive status epilepticus. JAMA1993;270:854-9.
3.
GamettWR. Status epilepticus. In: DiPiroJT, TalbertRL, HayesPE, YeeGC, MatzkeGR, PoseyLM, et al., eds. Pharmacotherapy a pathophysiologic approach, 2nd ed. Norwalk, CT: Appleton and Lange, 1993:864-78.
4.
WallaceSJ. Use of ethosuximide and valproate in the treatment of epilepsy. Neurol Clin1986;4:601-16.
5.
VajdaFJE, MihalyGW, MilesJL, DonnanGA, BladinPF. Rectal administration of sodium valproate in status epilepticus. Neurology1978;28:897-9.
6.
VajdaFJE. Valproic acid in the treatment of status epilepticus. Adv Neurol1983;34:519-28.
7.
BleckTP. Therapy for status epilepticus. Clin Neuropharmacol1983;6:255-69.
8.
ThorpyMJ. Rectal valproate syrup and status epilepticus. Neurology1980;30:1113-4.
9.
SneadOC, MilesMV. Treatment of status epilepticus in children with rectal sodium valproate. J Pediatr1985;106:323-5.
10.
AltrupU, GerlachG, ReithH, SaidMN, SpeckmannEJ. Effects of valproate in a model nervous system (buccal ganglia of helix pomatia): I. Antiepileptic actions. Epilepsia1992;33:743-52.
11.
WaltonNY, TreimanDM. Valproic acid treatment of experimental status epilepticus. Epilepsy Res1992;12:199-205.
12.
McleanMS, MacdonaldRL. Sodium valproate, but not ethosuximide, produces use and voltage dependent limitations of high-frequency repetitive firing of action potentials of mouse control neurons in cell culture. J Pharm Exp Ther1986;237:1001-11.
13.
CloydJC, KrielRL. Bioavailability of rectally administered valproic acid syrup. Neurology1981;31:1348-52.
14.
MoolenaarF, GreuingWJ, HuizingaT.Absorption rate and bioavailability of valproic acid and its sodium salt form rectal dosage forms. Eur J Clin Pharmacol1980;17:309-15.
